Molex, a parent company of Phillips Medisize, announces agreement to acquire Vectura Group Limited, expanding its inhaled drug delivery capabilities

Molex, a parent company of Phillips Medisize, a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, announced that it has signed an agreement, through its subsidiary Molex Asia Holdings LTD., to acquire Vectura Group Limited (Vectura) from Vectura Fertin Pharma Inc., a subsidiary of Philip Morris International (PMI) (NYSE: PM). Vectura is a leader in the design and formulation of inhaled drug delivery devices, based in Chippenham, United Kingdom.

“By combining the strengths of Phillips Medisize and Vectura, we can offer our pharmaceutical customers a broader portfolio of inhaled combination medicines and solutions and support our mission of helping people live healthier, more productive lives,” said Paul Chaffin, President of Phillips Medisize. “With our global reach, manufacturing scale and technical expertise, Phillips Medisize is uniquely positioned to help Vectura develop innovative new products for their customers, ultimately benefiting people living with chronic and acute diseases such as asthma and COPD.”